EYPT
ACHAT TOTAL: 10 600 titres (~52 258,00 $ US)
- Insiders
- Zaderej Karen L.
- Total bought
- $52,258
- Total sold
- —
- Last activity
- 2026-08-18
- Last synced
-
2026-08-25 17:08:49
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-26
EYPT presents a catastrophic risk profile: the Phase 3 failure of DURAVYU (LUGANO trial, primary endpoint missed) triggered a 67% stock collapse, and with a catalyst score of just 10 and no meaningful positive…
The first sentence of the analysis written for EYPT on 2026-08-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 93.4% | 91.4% | 89.9% | 79.9% | 77.9% | |
| Ebit Margin | -738.4% | -302.2% | -151.0% | -239.3% | -143.3% | |
| Ebitda Margin | -731.1% | -298.6% | -149.9% | -233.4% | -135.8% | |
| Operating Profit Margin | -776.0% | -337.1% | -163.1% | -240.6% | -149.6% | |
| Pretax Profit Margin | -738.5% | -302.2% | -153.7% | -247.0% | -158.1% | |
| Continuous Operations Profit Margin | -739.4% | -302.4% | -153.8% | -247.0% | -158.1% | |
| Net Profit Margin | -739.4% | -302.4% | -153.8% | -247.0% | -158.1% | |
| Bottom Line Profit Margin | -739.4% | -302.4% | -153.8% | -247.0% | -158.1% | |
| Current Ratio | 8.877 | 7.815 | 5.450 | 5.004 | 10.049 | |
| Quick Ratio | 8.828 | 7.768 | 5.389 | 4.920 | 9.896 | |
| Solvency Ratio | -3.968 | -1.578 | -0.791 | -1.188 | -0.704 | |
| Cash Ratio | 2.750 | 2.033 | 4.446 | 2.769 | 7.549 | |
| Price To Earnings Ratio | -5.763 | -3.211 | -12.698 | -1.277 | -6.030 | |
| Price To Earnings Growth Ratio | -0.157 | -0.117 | 0.378 | -0.037 | 0.141 | |
| Forward Price To Earnings Growth Ratio | -0.157 | -0.117 | 0.378 | -0.037 | 0.141 | |
| Price To Earnings Diluted Ratio | -5.763 | -3.211 | -12.698 | -1.277 | -6.030 | |
| Price To Earnings Diluted Growth Ratio | -0.157 | -0.117 | 0.378 | -0.037 | 0.141 | |
| Price To Book Ratio | 4.372 | 1.246 | 3.376 | 1.355 | 1.909 | |
| Price To Sales Ratio | 42.660 | 9.692 | 19.537 | 3.155 | 9.529 | |
| Price To Free Cash Flow Ratio | -5.499 | -3.219 | -559.124 | -1.945 | -7.005 | |
| Price To Operating Cash Flow Ratio | -5.574 | -3.323 | 479.505 | -2.009 | -7.026 | |
| Debt To Assets Ratio | 0.063 | 0.052 | 0.014 | 0.257 | 0.149 | |
| Debt To Equity Ratio | 0.074 | 0.065 | 0.018 | 0.481 | 0.213 | |
| Debt To Capital Ratio | 0.069 | 0.061 | 0.018 | 0.325 | 0.175 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.233 | 0.165 | |
| Financial Leverage Ratio | 1.189 | 1.244 | 1.334 | 1.872 | 1.428 | |
| Working Capital Turnover Ratio | 0.100 | 0.141 | 0.219 | 0.235 | 0.282 | |
| Operating Cash Flow Ratio | -6.485 | -2.574 | 0.030 | -1.882 | -2.118 | |
| Operating Cash Flow Sales Ratio | -7.654 | -2.917 | 0.041 | -1.570 | -1.356 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.014 | 1.032 | -0.858 | 1.033 | 1.003 | |
| Debt Service Coverage Ratio | 6,958.182 | -9,236.857 | -55.400 | -7.071 | -9.121 | |
| Interest Coverage Ratio | 7,376.788 | -10,418.143 | -60.198 | -31.244 | -10.054 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | -6.206 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -10.534 | -5.775 | 0.382 | -1.403 | -1.278 | |
| Capital Expenditure Coverage Ratio | -73.204 | -31.152 | 0.538 | -30.235 | -321.135 | |
| Dividend Paid And Capex Coverage Ratio | -73.204 | -31.152 | 0.538 | -30.235 | -321.135 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -5.491 | -2.643 | -9.025 | -0.842 | -4.240 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 93.4% | ▲2.0% | ▲6.9% |
| Ebit Margin | -738.4% | ▼-436.2% | ▼-423.6% |
| Ebitda Margin | -731.1% | ▼-432.4% | ▼-421.3% |
| Operating Profit Margin | -776.0% | ▼-438.9% | ▼-442.7% |
| Pretax Profit Margin | -738.5% | ▼-436.3% | ▼-418.6% |
| Continuous Operations Profit Margin | -739.4% | ▼-437.0% | ▼-419.3% |
| Net Profit Margin | -739.4% | ▼-437.0% | ▼-419.3% |
| Bottom Line Profit Margin | -739.4% | ▼-437.0% | ▼-419.3% |
| Current Ratio | 8.877 | ▲1.062 | ▲1.438 |
| Quick Ratio | 8.828 | ▲1.060 | ▲1.468 |
| Solvency Ratio | -3.967 | ▼-2.390 | ▼-2.322 |
| Cash Ratio | 2.750 | ▲0.717 | ▼-1.159 |
| Price To Earnings Ratio | -5.763 | ▼-2.552 | ▲0.033 |
| Price To Earnings Growth Ratio | -0.157 | ▼-0.040 | ▼-0.199 |
| Forward Price To Earnings Growth Ratio | -0.157 | ▼-0.040 | ▼-0.199 |
| Price To Earnings Diluted Ratio | -5.763 | ▼-2.552 | ▲0.033 |
| Price To Earnings Diluted Growth Ratio | -0.157 | ▼-0.040 | ▼-0.199 |
| Price To Book Ratio | 4.372 | ▲3.126 | ▲1.920 |
| Price To Sales Ratio | 42.660 | ▲32.968 | ▲25.745 |
| Price To Free Cash Flow Ratio | -5.499 | ▼-2.279 | ▲109.860 |
| Price To Operating Cash Flow Ratio | -5.574 | ▼-2.251 | ▼-97.888 |
| Debt To Assets Ratio | 0.063 | ▲0.010 | ▼-0.044 |
| Debt To Equity Ratio | 0.074 | ▲0.009 | ▼-0.096 |
| Debt To Capital Ratio | 0.069 | ▲0.008 | ▼-0.060 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.080 |
| Financial Leverage Ratio | 1.189 | ▼-0.054 | ▼-0.224 |
| Working Capital Turnover Ratio | 0.100 | ▼-0.040 | ▼-0.095 |
| Operating Cash Flow Ratio | -6.485 | ▼-3.912 | ▼-3.880 |
| Operating Cash Flow Sales Ratio | -7.654 | ▼-4.737 | ▼-4.963 |
| Free Cash Flow Operating Cash Flow Ratio | 1.014 | ▼-0.018 | ▲0.369 |
| Debt Service Coverage Ratio | 6958.182 | ▲16195.039 | ▲7428.235 |
| Interest Coverage Ratio | 7376.788 | ▲17794.931 | ▲8005.358 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲1.241 |
| Operating Cash Flow Coverage Ratio | -10.534 | ▼-4.759 | ▼-6.812 |
| Capital Expenditure Coverage Ratio | -73.204 | ▼-42.053 | ▲17.833 |
| Dividend Paid And Capex Coverage Ratio | -73.204 | ▼-42.053 | ▲17.833 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -5.491 | ▼-2.848 | ▼-1.043 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.34B | $419.4M | $899.1M | $130.6M | $352.0M | |
| Enterprise value | $1.26B | $341.6M | $622.7M | $81.3M | $212.6M | |
| EV / Sales | 40.14x | 7.89x | 13.53x | 1.96x | 5.76x | |
| EV / Op. cash flow | -5.25x | -2.71x | 332.11x | -1.25x | -4.24x | |
| EV / Free cash flow | -5.17x | -2.62x | -387.26x | -1.21x | -4.23x | |
| EV / EBITDA | -5.49x | -2.64x | -9.03x | -0.84x | -4.24x | |
| Net debt / EBITDA | 0.34x | 0.60x | 4.00x | 0.51x | 2.78x | |
| Current ratio | 8.88x | 7.82x | 5.45x | 5.00x | 10.05x | |
| Income quality | 1.03x | 0.96x | -0.03x | 0.64x | 0.86x | |
| Graham net-net | $3 | $5 | $6 | $2 | $5 | |
| Tax burden | 100.1% | 100.1% | 100.1% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 101.8% | 103.2% | 110.4% | |
| Working capital | $291.6M | $334.3M | $281.5M | $138.3M | $214.1M | |
| Invested capital | $311.9M | $363.4M | $291.8M | $145.7M | $239.6M | |
| Return on assets | -63.7% | -31.3% | -19.9% | -56.7% | -22.2% | |
| Operating ROA | -62.2% | -37.7% | -28.0% | -44.9% | -31.1% | |
| Return on tangible assets | -63.7% | -31.3% | -19.9% | -56.7% | -24.3% | |
| Return on equity | -75.8% | -38.9% | -26.6% | -106.1% | -31.7% | |
| Return on invested capital | -74.0% | -39.5% | -25.7% | -63.5% | -23.0% | |
| Return on capital employed | -74.5% | -39.5% | -25.7% | -68.3% | -23.1% | |
| Earnings yield | -17.3% | -31.2% | -7.9% | -78.3% | -16.6% | |
| Free cash flow yield | -18.2% | -31.1% | -0.2% | -51.4% | -14.3% | |
| Capex / Op. cash flow | -1.4% | -3.2% | 185.8% | -3.3% | -0.3% | |
| Capex / Depreciation | 142.1% | 263.1% | 750.6% | 87.9% | 5.6% | |
| Capex / Sales | 10.5% | 9.4% | 7.6% | 5.2% | 0.4% | |
| SG&A / Sales | 164.8% | 121.3% | 112.5% | 145.7% | 143.7% | |
| R&D / Sales | 704.6% | 307.2% | 140.5% | 119.9% | 77.2% | |
| Stock comp / Sales | 88.8% | 84.9% | 26.2% | 34.2% | 20.2% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 8.6% | |
| Days sales outstanding | 8d | 5d | 6d | 137d | 181d | |
| Days payables outstanding | 1853d | 1153d | 513d | 259d | 330d | |
| Operating cycle | 328d | 232d | 314d | 263d | 343d | |
| Cash conversion cycle | -1525d | -921d | -198d | 4d | 13d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+219.1%EV / Sales ▲+408.5%EV / EBITDA ▼-107.7%EV / Op. cash flow ▼-2.538Earnings yield ▲+0.139
Profitability
Return on equity ▼-0.369Return on assets ▼-0.325Return on invested capital ▼-0.345Return on capital employed ▼-0.350Operating ROA ▼-0.245Income quality ▲+0.071Tax burden ▲+0.001
Efficiency
Days sales outstanding ▲+2.454Days payables outstanding ▲+700.744Operating cycle ▲+96.107Cash conversion cycle ▼-604.637Capex / Sales ▲+0.011R&D / Sales ▲+3.974
Balance-sheet strength
Current ratio ▲+1.062Net debt / EBITDA ▼-0.258Working capital ▼-42627000.000Invested capital ▼-51581000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+280.2%EV / Sales ▲+597.4%EV / EBITDA ▼-29.5%EV / Op. cash flow ▼-1.001Earnings yield ▼-0.007
Profitability
Return on equity ▼-0.441Return on assets ▼-0.415Return on invested capital ▼-0.510Return on capital employed ▼-0.514Operating ROA ▼-0.311Income quality ▲+0.178Tax burden ▲+0.001
Efficiency
Days sales outstanding ▼-173.784Days payables outstanding ▲+1523.620Operating cycle ▼-14.891Cash conversion cycle ▼-1538.511Capex / Sales ▲+0.100R&D / Sales ▲+6.274
Balance-sheet strength
Current ratio ▼-1.172Net debt / EBITDA ▼-2.435Working capital ▲+77544000.000Invested capital ▲+72290000.000Intangibles / Total assets ▼-0.086
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-21 EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT) Roughly seven out of every ten dollars invested in EyePoint Pharmaceuticals (NASDAQ: EYPT) common stock was wiped out when shares fell nearly 67% following the
- 2026-08-21 EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT) NEW YORK--(BUSINESS WIRE)--Roughly seven out of every ten dollars invested in EyePoint Pharmaceuticals (NASDAQ: EYPT) common stock was wiped out when shares fell nearly 67% following the Company''s disclosure that DURAVYU missed the prespecified primary endpoint in the Phase 3 LUGANO wet AMD trial. If you held EYPT shares through that decline, you are encouraged to have your EYPT losses reviewed now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at.
- 2026-08-20 EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals PR
- 2026-08-19 EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown Eyepoint Pharmaceuticals (EYPT) plunged ~70% after its LUGANO Phase 3 trial for Duravyu in wet AMD failed the primary endpoint due to an anomalous cohort. EYPT''s management argues the failure was driven by nine patients (4%) with vision loss unrelated to wet AMD, and highlights strong secondary endpoints and durability advantages. Upcoming LUCIA Phase 3 data in Q4 2026 is pivotal; a positive result could revive the Duravyu program and restore investor confidence.
- 2026-08-19 EyePoint’s DURAVYU Misses Primary Endpoint in Phase III Wet AMD Trial Eyepoint Pharmaceuticals (NASDAQ: EYPT) reported topline results from LUGANO, the first of two Phase III trials evaluating DURAVYU, a vorolanib intravitreal insert, in patients with wet age-related macular degeneration, or wet AMD. The study did not meet its primary non-inferiority endpoint in the full analysis population versus on-label aflibercept. LUGANO enrolled 432 patients, randomized equally to
- 2026-08-18 These Analysts Slash Their Forecasts On EyePoint EyePoint Inc. (NASDAQ:EYPT) on Monday released topline results from its pivotal Phase 3 LUGANO clinical trial evaluating DURAVYU for the treatment of wet age-related macular degeneration.
- 2026-08-18 EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal EyePoint''s Duravyu misses the phase III wet AMD study''s primary goal, sending shares down 67%, but shows lower treatment burden and durable disease control.
- 2026-08-18 EyePoint, Inc. (EYPT) Discusses LUGANO Top Line Data From Phase III Wet AMD Trial for DURAVYU Transcript EyePoint, Inc. (EYPT) Discusses LUGANO Top Line Data From Phase III Wet AMD Trial for DURAVYU Transcript
- 2026-08-17 EyePoint Stock Plummets on Mixed Primary Data From Blindness Drug Study EyePoint Inc. (NASDAQ:EYPT) stock plunged on Monday after the company released topline results from its pivotal Phase 3 LUGANO clinical trial evaluating DURAVYU for the treatment of wet age-related macular degeneration.
- 2026-08-17 EyePoint''s eye drug misses main goal in late-stage trial EyePoint said on Monday its experimental eye drug failed to meet its main goal in a late-stage trial.